caa a22 4500 463185625 CHVBK 20180406164852.0 cr unu---uuuuu 170326e20070401xx s 000 0 eng 10.1007/s00726-006-0386-y doi (NATIONALLICENCE)springer-10.1007/s00726-006-0386-y Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract [Elektronische Daten] [G. Palmieri, L. Montella, C. Aiello, F. Barbieri, D. Di Vizio, S. Schulz, S. Beninati, A. Budillon, M. Caraglia, L. Insabato, T. Florio] Summary.: Imatinib, a tyrosine kinase inhibitor directed against the enzymatic domain of KIT protein, was found to produce dramatic clinical responses in metastatic gastrointestinal stromal tumors (GISTs). However, resistance usually develops thus determining treatment failure. The present study was performed to analyse the expression of somatostatin receptor (SSTR) subtypes, modulators of tissue transglutaminase, in a series of GISTs and leiomyosarcomas by immunohistochemistry to identify a new potential therapeutic target. Sixteen cases (8 males and 8 females, age range: 38-73; 11 GISTs, 4 leiomyosarcomas, 1 leiomyoma) were studied. Immunohistochemical detection of the relevant SSTRs was performed on paraffin-embedded tissue sections, stained with polyclonal antibodies directed against the five somatostatin receptor subtypes. We found 7 out of 16 (44%) tumors expressing all SSTRs and 14 out of 16 (87%) tumors positive for at least 3 subtypes. SSTR2A was the most represented subtype in the tumors studied, being expressed in approximately 70% of cases exhibiting an intense labeling in most of these cases. The significant expression of SSTRs shown in this series of GISTs and gastrointestinal leiomyosarcomas suggests a potential therapeutic target to be explored alone and/or in combination with other therapeutic agents in the setting of refractory GI stromal tumors. Springer-Verlag, 2007 Keywords: GIST - Gastrointestinal leiomyosarcomas - Tissue transglutaminase - Somatostatin receptor - Immunohistochemistry - Imatinib nationallicence Palmieri G. Department of Molecular and Clinical Endocrinology and Oncology, "Federico II” University, Naples, Italy aut Montella L. Department of Molecular and Clinical Endocrinology and Oncology, "Federico II” University, Naples, Italy aut Aiello C. Pharmacology and Neuroscience, National Institute for Cancer Research, Genova, Italy aut Barbieri F. Section of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, Genova, Italy aut Di Vizio D. Department of Biomorphological and Functional Science, Unit of Pathology, University "Federico II”, Naples, Italy aut Schulz S. Department of Pharmacology and Toxicology, Otto-von-Guericke-University, Magdeburg, Germany aut Beninati S. Department of Biology, Second University of Rome "Tor Vergata”, Rome, Italy aut Budillon A. Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours "G. Pascale”, Naples, Italy aut Caraglia M. Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours "G. Pascale”, Naples, Italy aut Insabato L. Department of Biomorphological and Functional Science, Unit of Pathology, University "Federico II”, Naples, Italy aut Florio T. Section of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, Genova, Italy aut Amino Acids Springer-Verlag 32/3(2007-04-01), 395-400 0939-4451 32:3<395 2007 32 726 https://doi.org/10.1007/s00726-006-0386-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00726-006-0386-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Palmieri G. Department of Molecular and Clinical Endocrinology and Oncology, "Federico II” University, Naples, Italy aut NATIONALLICENCE 700 1- Montella L. Department of Molecular and Clinical Endocrinology and Oncology, "Federico II” University, Naples, Italy aut NATIONALLICENCE 700 1- Aiello C. Pharmacology and Neuroscience, National Institute for Cancer Research, Genova, Italy aut NATIONALLICENCE 700 1- Barbieri F. Section of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, Genova, Italy aut NATIONALLICENCE 700 1- Di Vizio D. Department of Biomorphological and Functional Science, Unit of Pathology, University "Federico II”, Naples, Italy aut NATIONALLICENCE 700 1- Schulz S. Department of Pharmacology and Toxicology, Otto-von-Guericke-University, Magdeburg, Germany aut NATIONALLICENCE 700 1- Beninati S. Department of Biology, Second University of Rome "Tor Vergata”, Rome, Italy aut NATIONALLICENCE 700 1- Budillon A. Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours "G. Pascale”, Naples, Italy aut NATIONALLICENCE 700 1- Caraglia M. Department of Experimental Oncology, Experimental Pharmacology Unit, National Institute of Tumours "G. Pascale”, Naples, Italy aut NATIONALLICENCE 700 1- Insabato L. Department of Biomorphological and Functional Science, Unit of Pathology, University "Federico II”, Naples, Italy aut NATIONALLICENCE 700 1- Florio T. Section of Pharmacology, Department of Oncology, Biology and Genetics, University of Genova, Genova, Italy aut NATIONALLICENCE 773 0- Amino Acids Springer-Verlag 32/3(2007-04-01), 395-400 0939-4451 32:3<395 2007 32 726 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer